Expertise in
11
conditions

Dr. Robert Doebele

Oncology
University Of Colorado Hospital
1665 Aurora Ct Fl 2, 
Aurora, CO 
Clinical Trials:Currently Recruiting for 3 Trials
Expertise in
11
conditions
University Of Colorado Hospital
1665 Aurora Ct Fl 2, 
Aurora, CO 

Overview

Robert Doebele is an Oncologist in Aurora, Colorado. Dr. Doebele is highly rated in 11 conditions, according to our data. His top areas of expertise are Lung Cancer, Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer.

His clinical research consists of co-authoring 155 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in CO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

University of Colorado Hospital
1665 Aurora Ct Fl 2, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers
Enrollment Status: Recruiting
Publish Date: August 06, 2025
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer
Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer
Enrollment Status: Recruiting
Publish Date: February 06, 2025
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological
Study Drug: CAB-AXL-ADC
Study Phase: Phase 1/Phase 2
A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug, Procedure
Study Drug: Osimertinib
Study Phase: Phase 2
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Enrollment Status: Terminated
Publish Date: June 13, 2024
Intervention Type: Drug
Study Drug: TPX-0046
Study Phase: Phase 1/Phase 2
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
Enrollment Status: Terminated
Publish Date: August 08, 2023
Intervention Type: Biological
Study Drug: GRN-1201+Pembrolizumab
Study Phase: Phase 2
A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer
A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 11, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
View 7 Less Clinical Trials

155 Total Publications

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.
Journal: Science signaling
Published: December 23, 2025
Similar Doctors
Expertise in
13
conditions
Dr. D Ross
Oncology
Expertise in
13
conditions
Dr. D Ross
Oncology

University Of Colorado Hospital

1665 Aurora Ct Fl 2, 
Aurora, CO 
 (0.4 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

D Ross is an Oncologist in Aurora, Colorado. Dr. Ross is highly rated in 13 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

Expertise in
29
conditions
Dr. Breelyn Wilky
Oncology
Expertise in
29
conditions
Dr. Breelyn Wilky
Oncology

University Of Colorado Hospital

1665 Aurora Ct, 
Aurora, CO 
 (0.2 miles away)
720-848-0300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Breelyn Wilky is an Oncologist in Aurora, Colorado. Dr. Wilky is highly rated in 29 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Desmoid Tumor, and Gastrointestinal Stromal Tumor.

Expertise in
31
conditions
Dr. Anthony Elias
Oncology
Expertise in
31
conditions
Dr. Anthony Elias
Oncology

University Of Colorado Hospital

1665 Aurora Ct, 
Aurora, CO 
 (0.2 miles away)
720-848-0300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Elias is an Oncologist in Aurora, Colorado. Dr. Elias is highly rated in 31 conditions, according to our data. His top areas of expertise are Breast Cancer, Adult Soft Tissue Sarcoma, Liposarcoma, and Synovial Sarcoma.

Frequently Asked Questions about Dr. Robert Doebele

How do I make an appointment with Dr. Robert Doebele?

You can book an appointment with Dr. Robert Doebele by calling their office at 720-848-0000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert Doebele a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert Doebele is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert Doebele specialize in?

While Dr. Robert Doebele is a Oncology, they have specific expertise in Lung Cancer, Lung Adenocarcinoma, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Robert Doebele participate in research or clinical trials?

Yes. Dr. Robert Doebele has published 155 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Robert Doebele's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Robert Doebele accept my insurance?

Dr. Robert Doebele accepts most major insurance plans, including UnitedHealthcare. We recommend calling the office directly at 720-848-0000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Doebele's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile